Prostate cancer; Systems pathology; Wnt/β-catenin pathwayCàncer de pròstata; Patologia de sistemes; Via Wnt/β-cateninaCáncer de próstata; Patología de sistemas; Vía Wnt/β-cateninaOBJECTIVES: To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. RESULTS: The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas whe...
<p>Immunohistological staining was performed with H102 (panel A) and pT120 (panel B) antibodies on s...
<div><p>Prostate cancer is a major cause of male death in the Western world, but few frequent geneti...
Inhibition of the androgen receptor (AR) is the main strategy to treat advanced prostate cancers. AR...
To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and hu...
Objectives: At present, sufficient prognostic markers for prostate cancer (PCa) progression are stil...
peer reviewedInhibition of the androgen receptor (AR) is the main strategy to treat advanced prostat...
Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential im...
Prostate cancer is a significant health problem for men in the western world. Of particular concern...
BACKGROUND—Prostate cancer is the second leading cause of cancer death in men, and early detectio...
Purpose: To investigate the relationships among the Wnt/β-catenin pathway, androgen receptor (AR), a...
Prostate cancer (PCa) is the second most common cancer among the male population. Conventional thera...
Aberrant activation of the Wnt pathway is emerging as a frequent event during prostate cancer that c...
β-catenin in its role as a nuclear signaling molecule has been implicated in prostate carcinogenesis...
Further understanding of the molecular mechanisms responsible for prostate cancer (CaP) development ...
Prostate cancer (PrCa) is the second leading cause of cancer related mortality in North American me...
<p>Immunohistological staining was performed with H102 (panel A) and pT120 (panel B) antibodies on s...
<div><p>Prostate cancer is a major cause of male death in the Western world, but few frequent geneti...
Inhibition of the androgen receptor (AR) is the main strategy to treat advanced prostate cancers. AR...
To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and hu...
Objectives: At present, sufficient prognostic markers for prostate cancer (PCa) progression are stil...
peer reviewedInhibition of the androgen receptor (AR) is the main strategy to treat advanced prostat...
Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential im...
Prostate cancer is a significant health problem for men in the western world. Of particular concern...
BACKGROUND—Prostate cancer is the second leading cause of cancer death in men, and early detectio...
Purpose: To investigate the relationships among the Wnt/β-catenin pathway, androgen receptor (AR), a...
Prostate cancer (PCa) is the second most common cancer among the male population. Conventional thera...
Aberrant activation of the Wnt pathway is emerging as a frequent event during prostate cancer that c...
β-catenin in its role as a nuclear signaling molecule has been implicated in prostate carcinogenesis...
Further understanding of the molecular mechanisms responsible for prostate cancer (CaP) development ...
Prostate cancer (PrCa) is the second leading cause of cancer related mortality in North American me...
<p>Immunohistological staining was performed with H102 (panel A) and pT120 (panel B) antibodies on s...
<div><p>Prostate cancer is a major cause of male death in the Western world, but few frequent geneti...
Inhibition of the androgen receptor (AR) is the main strategy to treat advanced prostate cancers. AR...